# Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia

> **NCT05369377** · PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT05369377
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-05-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05369377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05369377, "Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05369377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*